Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions
Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers.
Decera Clinical Education Oncology Podcast · Jamie E. Chaft MD, Scot Niglio MD, John L. Marshall MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:
- Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)
- Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibition
- Neoadjuvant treatment with immune checkpoint inhibitors
- Financial considerations when selecting chemotherapy vs immuno-oncology
Presenters:
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Scot Niglio, MD
Medical Oncologist
Bethesda, Maryland
Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/31vQtqb
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.